Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Millennium Retains Velcade U.S. Rights; J&J Picks Up Half Of R&D Costs

Executive Summary

Millennium's Velcade agreement with Johnson & Johnson allows the biotech company to retain rights to the oncologic in the U.S., while requiring J&J to pick up nearly half of future worldwide development costs

You may also be interested in...



Big Pharma Seeking Simple Deals In Complex Biotech Licensing Environment

Large pharmaceutical manufacturers generally prefer biotech licensing deals that have simple structures, Bristol-Myers Squibb VP-Business Development Graham Brazier said

Big Pharma Seeking Simple Deals In Complex Biotech Licensing Environment

Large pharmaceutical manufacturers generally prefer biotech licensing deals that have simple structures, Bristol-Myers Squibb VP-Business Development Graham Brazier said

Gilead Leads Biotech Rebound In 2003: Product Stories Play Well

Gilead Sciences is leading a new wave of biotech stocks attempting to break out of the start-up phase to become full-fledged biopharma companies

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS042098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel